Key result
Urine DOAC dipsticks detect relevant anticoagulation with 100% accuracy vs blood tests in acute ischemic stroke.
Why the study?
Point-of-care urine testing offers a promising approach to rapidly assess DOAC presence, but its utility needed evaluation in patients with acute ischemic stroke or transient ischemic attack.
Does a urine-based DOAC dipstick test accurately and rapidly detect factor-Xa-inhibitors in acute ischemic stroke patients compared to standard blood-based testing?
Observational (n=44)
Single-blind
No
Does a urine-based DOAC dipstick test accurately and rapidly detect factor-Xa-inhibitors in acute ischemic stroke patients compared to standard blood-based testing?
A urine-based DOAC dipstick test provides a rapid and highly accurate method for detecting factor-Xa inhibitors in acute ischemic stroke patients, potentially saving critical time for acute treatment decisions.
Answers are grounded in this paper and cite their sources.
May support rapid urine DOAC testing in acute stroke; leaves open validation in larger prospective cohorts before adoption.
Introduction: Direct oral anticoagulants (DOACs) have become widely used in clinical practice for preventing thromboembolic events. Point-of-care testing methods, particularly those based on urine samples, offer a promising approach for rapid and accurate assessment of DOAC presence. This pilot study aims to evaluate the utility of a urine-based DOAC dipstick test as a point-of-care tool for identifying DOAB presence in acute ischemic stroke (AIS) or transient ischemic attack (TIA) patients. Patients and methods: = 23) and 21 patients without DOAC-intake (control-group) remained for analyses. The urine-based DOAC dipstick test and parallel blood-based specific DOAC-level assessment were performed in all patients. Time-intervals of sampling urine/blood sampling and result of DOAC-test were recorded to analyze a potential time benefit based on dipstick evaluation. Results: The urine-based DOAC dipstick test demonstrated high sensitivity (100%) and specificity (100%), correctly identifying all patients with anticoagulatory activity due to DOAC intake (i.e., anti-Xalevel ≥30 ng/mL). Moreover, the visual readout of the test provided semiquantitative information on drug-specific anti-Xa levels, showing a sensitivity of 83% and specificity of 93% to detect anti-Xa levels ≥120 ng/mL. The dipstick test exhibited a median time-benefit of 2:25 h compared to standard blood-based DOAC-level testing. Discussion: The results of this pilot study underline the efficacy of urine-based point-of-care testing as a rapid and reliable method for assessing DOAC presence in patients with acute ischemic stroke. Conclusion: : Clinicaltrails.org identifier [NCT06037200].
No takes yet. Share an insight, caveat, or question.
Doeppner et al. (2023) conducted an observational in Acute ischemic stroke or transient ischemic attack (n=44). Urine-based DOAC dipstick test vs. Standard blood-based specific DOAC-level assessment was evaluated on Sensitivity to detect relevant anticoagulatory activity (drug-specific anti-Xa level ≥30 ng/mL) (100% sensitivity). The urine-based DOAC dipstick test demonstrated 100% sensitivity and 100% specificity in identifying relevant anticoagulatory activity compared to standard blood tests in acute ischemic stroke patients.
Synapse has enriched 10 related papers. Consider them for comparative context: